AR112188A1 - Composición oral de pectina cítrica y papaína, métodos para prepararla en formas de dosificación de cápsula blanda y jarabe - Google Patents

Composición oral de pectina cítrica y papaína, métodos para prepararla en formas de dosificación de cápsula blanda y jarabe

Info

Publication number
AR112188A1
AR112188A1 ARP180101347A AR112188A1 AR 112188 A1 AR112188 A1 AR 112188A1 AR P180101347 A ARP180101347 A AR P180101347A AR 112188 A1 AR112188 A1 AR 112188A1
Authority
AR
Argentina
Prior art keywords
papain
oral composition
pectin
prepare
methods
Prior art date
Application number
Other languages
English (en)
Inventor
Mauricio Dobboletta
Original Assignee
Brix S R L
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brix S R L filed Critical Brix S R L
Priority to ARP180101347 priority Critical patent/AR112188A1/es
Priority to PCT/US2019/031326 priority patent/WO2019226349A1/en
Publication of AR112188A1 publication Critical patent/AR112188A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/732—Pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/75—Rutaceae (Rue family)
    • A61K36/752—Citrus, e.g. lime, orange or lemon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4873—Cysteine endopeptidases (3.4.22), e.g. stem bromelain, papain, ficin, cathepsin H
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/22—Cysteine endopeptidases (3.4.22)
    • C12Y304/22002—Papain (3.4.22.2)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Diabetes (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Composición oral a base de pectina y papaína para disminuir los niveles de IGF-1 libre en plasma de personas que lo necesitan, dicha composición comprende pectina de por lo menos 65% de ácido D-galacturónico y papaína con una actividad proteolítica de por lo menos 6.000 U/mg, en donde la pectina y la papaína tienen una relación en peso efectiva de aproximadamente 250:3, respectivamente, y se encuentran humectadas por medio de al menos dos polioles de C₃₋₆, siendo el pH de la composición del orden de 6 obtenido con el agregado de al menos una alcanolamida de C₂₋₆, y comprendiendo además emulsionantes, conservantes y solventes farmacéuticamente aceptables. Métodos para preparar dicha composición oral en cápsula blanda y en jarabe. Método para disminuir los niveles de IGF-1 libre en plasma de personas que lo necesitan con dicha composición oral; que comprende administrara dichas personas una dosificación comprendiendo al menos aproximadamente 250 mg de pectina y al menos aproximadamente 3 mg de papaína cada por lo menos 12 horas durante al menos 28 días. Uso de pectina y papaína en forma conjunta para preparar dicha composición oral.
ARP180101347 2018-05-22 2018-05-22 Composición oral de pectina cítrica y papaína, métodos para prepararla en formas de dosificación de cápsula blanda y jarabe AR112188A1 (es)

Priority Applications (2)

Application Number Priority Date Filing Date Title
ARP180101347 AR112188A1 (es) 2018-05-22 2018-05-22 Composición oral de pectina cítrica y papaína, métodos para prepararla en formas de dosificación de cápsula blanda y jarabe
PCT/US2019/031326 WO2019226349A1 (en) 2018-05-22 2019-05-08 Oral composition of citrus pectin and papain to decrease plasma free igf-1 levels in individuals who need it and methods of preparation in soft capsule and syrup dosage forms

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ARP180101347 AR112188A1 (es) 2018-05-22 2018-05-22 Composición oral de pectina cítrica y papaína, métodos para prepararla en formas de dosificación de cápsula blanda y jarabe

Publications (1)

Publication Number Publication Date
AR112188A1 true AR112188A1 (es) 2019-10-02

Family

ID=68382491

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP180101347 AR112188A1 (es) 2018-05-22 2018-05-22 Composición oral de pectina cítrica y papaína, métodos para prepararla en formas de dosificación de cápsula blanda y jarabe

Country Status (2)

Country Link
AR (1) AR112188A1 (es)
WO (1) WO2019226349A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115212226A (zh) * 2021-04-20 2022-10-21 涛护集团有限公司 果胶在制备用于改善/逆转因病毒或药物损伤引起的慢性肾脏病的保健品/药物中的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8916541B2 (en) * 2011-01-05 2014-12-23 Better Health Publishing, Inc. Synergistic combination of honokiol and modified citrus pectin in cancer therapy
US8333961B2 (en) * 2007-07-03 2012-12-18 Privitera James R Natural liniment for treatment of skin cancers
AR102008A1 (es) * 2015-09-24 2017-01-25 Brix S R L Ingrediente farmacéutico activo (ifa) oleoso para el tratamiento de afecciones de la piel, composiciones que lo comprenden y su uso para prepararlas
WO2017184851A1 (en) * 2016-04-20 2017-10-26 La Jolla Pharmaceutical Company Compositions and methods for treating cancer

Also Published As

Publication number Publication date
WO2019226349A1 (en) 2019-11-28

Similar Documents

Publication Publication Date Title
WO2015183963A3 (en) Therapeutic compositions including redox-active parabenzoquinones and uses thereof
WO2016004093A3 (en) Therapeutic compositions including galectin-3 inhibitors and uses thereof
CO2019000938A2 (es) Moduladores nmda espiro-lactam y métodos de uso de los mismos
CO2020009670A2 (es) Composiciones que comprenden microbiota coseleccionada y métodos para su uso
CO2019000945A2 (es) Moduladores del receptor nmda espiro-lactam y uso de los mismos
CO5680456A2 (es) Composiciones de vacunas que comprenden lipooligosacaridos del inmunotipo l2 y/o l3 a partir de lgtb-neisseria minigitidis
CO2019000943A2 (es) Moduladores del receptor nmda espiro-lactam y uso de los mismos
EA200601761A1 (ru) Композиции в качестве адъювантов для усиления иммунных ответов на вакцины и способы их применения
CO2019000944A2 (es) Moduladores del receptor nmda spiro-lactam y bis-spiro-lactam y uso de los mismos
AR105027A1 (es) Métodos de tratamiento del cáncer de mama localmente avanzado o metastásico usando antagonistas del eje de pd-1 y taxanos
CO2019000941A2 (es) Moduladores del receptor nmda espiro-lactam y uso de los mismos
WO2015183995A3 (en) Therapeutic compositions including frataxin, lactoferrin, and mitochondrial energy generating enzymes, and uses thereof
EA202191079A1 (ru) Способы лечения синдрома ретта с применением фенфлурамина
CL2019003441A1 (es) Puestos de mic-1 y usos de estos.
AR112166A1 (es) Composiciones terapéuticas y métodos para el tratamiento de hepatitis b
CL2019003533A1 (es) Uso de vibegron para tratar vejiga sobreactiva.
AR112188A1 (es) Composición oral de pectina cítrica y papaína, métodos para prepararla en formas de dosificación de cápsula blanda y jarabe
DK1091733T3 (da) (-)-Pseudoephedrin som et sympatomimetisk lægemiddel
MX2022006940A (es) Composiciones farmaceuticas.
WO2015183985A3 (en) Therapeutic compositions including naphthoquinones and uses thereof
WO2019010301A8 (en) Treatment of heart disease by inhibition of the action of muscle a-kinase anchoring protein (makap)
DOP2022000004A (es) Composiciones farmacéuticas resistentes a la descarga de dosis que comprenden venirunad
AR046665A1 (es) Formulaciones orales de desoxipeganina y sus usos
MX2022008036A (es) Nuevo uso de formulacion inmunogenica bcg que expresa una proteina de virus respiratorio sincicial contra hmpv.
AR120399A1 (es) Un método de tratamiento de un cáncer positivo para dll3